Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Doxorubicin hydrochloride
Cat. No.:
OB0225LY-0286
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Doxorubicin hydrochloride is a broad-spectrum chemotherapeutic drug belonging to the anthracycline class of antibiotics with antitumor activity.
Synonym:
Adriamycin; Doxorubicin (Adriamycin) HCl; Hydroxydaunorubicin hydrochloride; DOX hydrochloride; NSC 123127; 25316-40-9; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8S)-cis)-
CAS No.:
25316-40-9
Compound CID:
443939
Formula:
C27H29NO11·HCl
Formula Weight:
579.99
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Doxorubicin hydrochloride can be used in proliferation studies of tumor cells or play an important role in cell cycle regulation studies.
Library Information
Targets:
DNA topoisomerase family
Receptors:
DNA topoisomerase I; DNA topoisomerase II
Pathways:
Apoptosis; Chromatin/Epigenetic; Antibody-drug Conjugate/ADC Related; Proteases/Proteasome; Autophagy; Microbiology/Virology; DNA damage/DNA repair; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-4
Plate Location:
f5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 94.83 mM
Water Max Solubility:
50 mg/mL; 86.2 mM





